Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 121 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]
2. Cita con resumen
Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]
3. Cita con resumen
Anónimo. Prothrombin complex concentrates to reverse warfarin-related bleeding. Med Lett Drugs Ther 2011;53:78-9. [Ref.ID 91712]
4. Cita con resumen
Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010;33:713-26. [Ref.ID 89267]
5. Cita con resumen
Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO Trial): a randomized controlled trial. PLOS Medicine 2008;5:1462-72. [Ref.ID 84385]
6.Enlace a cita original Cita con resumen
Tamura T, Morgan SL, Takimoto H. Vitamina K and the prevention of fractures. Arch Intern Med 2007;167:94. [Ref.ID 78840]
7. Cita con resumen
Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ. Vitamin K and the prevention of fractures. Systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:1256-61. [Ref.ID 77397]
8. Cita con resumen
DeZee KJ, Shimeall WT, Douglas KM, Shumway NM, O'Malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K). A meta-analysis. Arch Intern Med 2006;166:391-7. [Ref.ID 76257]
9. Cita con resumen
Anónimo. Vitamin K and anticoagulation. Lancet 2004;363:2149. [Ref.ID 70565]
10. Cita con resumen
Crowther C, Henderson-Smart D. Prenatal phenobarbital before very-preterm birth and neurodevelopmental outcome. Lancet 2002;360:1529-30. [Ref.ID 64079]
11.
Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002;36:1512-7. [Ref.ID 63528]
12.
Libby EN, García DA. A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med 2002;162:1893-6. [Ref.ID 63390]
13.Tiene citas relacionadas
Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention in adults. Clinical applications. JAMA 2002;287:3127-9. [Ref.ID 62543]
14.Tiene citas relacionadas
Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults. Scientific review. JAMA 2002;287:3116-26. [Ref.ID 62542]
15.Tiene citas relacionadas Cita con resumen
McElhatton P. Teratogenic drugs - part 2. Adv Drug React Bull 2002;214:819-22. [Ref.ID 62252]
17.Tiene citas relacionadas
Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001;135:393-400. [Ref.ID 58574]
18.Tiene citas relacionadas
Bussey HI. Managing excessive warfarin anticoagulation. Ann Intern Med 2001;135:460-2. [Ref.ID 58519]
19.
Szulc P, Meunier P-J. Is vitamin K deficiency a risk factor for osteoporosis in Crohn's disease?. Lancet 2001;357:1995-6. [Ref.ID 57397]
20.
Autret-Leca E, Jonville Béra A-P. Vitamin K in neonates: how to administer, when and to whom. Paediatr Drugs 2001;3:1-8. [Ref.ID 56507]
Seleccionar todas
 
 1 a 20 de 121 siguiente >>